DBV Technologies (DBVT) Competitors

$19.84 +0.24 (+1.22%)

Closing price 04:00 PM Eastern

Extended Trading

$19.85 +0.01 (+0.05%)

As of 04:10 PM Eastern

DBVT vs. NNNN, KNSA, CRNX, AMRX, and MANE

Should you buy DBV Technologies stock or one of its competitors? MarketBeat compares DBV Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DBV Technologies include Anbio Biotechnology (NNNN), Kiniksa Pharmaceuticals International (KNSA), Crinetics Pharmaceuticals (CRNX), Amneal Pharmaceuticals (AMRX), and MANE (MANE). These companies are all part of the "pharmaceutical products" industry.

How does DBV Technologies compare to Anbio Biotechnology?

DBV Technologies (NASDAQ:DBVT) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

DBV Technologies has a beta of -0.96, meaning that its stock price is 196% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.71, meaning that its stock price is 371% more volatile than the broader market.

Anbio Biotechnology has higher revenue and earnings than DBV Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	N/A	N/A	-$146.95M	-$4.46	N/A
Anbio Biotechnology	$8.65M	417.19	$6.40M	N/A	N/A

In the previous week, DBV Technologies had 3 more articles in the media than Anbio Biotechnology. MarketBeat recorded 4 mentions for DBV Technologies and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.19 beat DBV Technologies' score of 0.47 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
DBV Technologies	Neutral
Anbio Biotechnology	Positive

DBV Technologies presently has a consensus target price of $40.25, suggesting a potential upside of 102.87%. Given DBV Technologies' stronger consensus rating and higher possible upside, equities research analysts plainly believe DBV Technologies is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.67
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Anbio Biotechnology has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. Anbio Biotechnology's return on equity of 0.00% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
Anbio Biotechnology	N/A	N/A	N/A

71.7% of DBV Technologies shares are held by institutional investors. 1.4% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

DBV Technologies and Anbio Biotechnology tied by winning 7 of the 14 factors compared between the two stocks.

How does DBV Technologies compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and DBV Technologies (NASDAQ:DBVT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 1.4% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, DBV Technologies had 1 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 4 mentions for DBV Technologies and 3 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.06 beat DBV Technologies' score of 0.47 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kiniksa Pharmaceuticals International has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.96, meaning that its share price is 196% less volatile than the broader market.

Kiniksa Pharmaceuticals International currently has a consensus target price of $60.86, indicating a potential upside of 3.96%. DBV Technologies has a consensus target price of $40.25, indicating a potential upside of 102.87%. Given DBV Technologies' higher probable upside, analysts plainly believe DBV Technologies is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
DBV Technologies	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.67

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to DBV Technologies' net margin of -2,895.37%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

Kiniksa Pharmaceuticals International has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	6.65	$59.01M	$0.90	65.04
DBV Technologies	N/A	N/A	-$146.95M	-$4.46	N/A

Summary

Kiniksa Pharmaceuticals International beats DBV Technologies on 11 of the 15 factors compared between the two stocks.

How does DBV Technologies compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and DBV Technologies (NASDAQ:DBVT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

DBV Technologies has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$18.07M	223.55	-$465.32M	-$5.13	N/A
DBV Technologies	N/A	N/A	-$146.95M	-$4.46	N/A

In the previous week, Crinetics Pharmaceuticals had 29 more articles in the media than DBV Technologies. MarketBeat recorded 33 mentions for Crinetics Pharmaceuticals and 4 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 0.47 beat Crinetics Pharmaceuticals' score of -0.04 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 1.4% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Crinetics Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.96, meaning that its stock price is 196% less volatile than the broader market.

Crinetics Pharmaceuticals has a net margin of -2,747.18% compared to DBV Technologies' net margin of -2,895.37%. Crinetics Pharmaceuticals' return on equity of -43.96% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

Crinetics Pharmaceuticals currently has a consensus price target of $76.13, indicating a potential upside of 98.71%. DBV Technologies has a consensus price target of $40.25, indicating a potential upside of 102.87%. Given DBV Technologies' higher probable upside, analysts plainly believe DBV Technologies is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
DBV Technologies	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.67

Summary

Crinetics Pharmaceuticals beats DBV Technologies on 10 of the 16 factors compared between the two stocks.

How does DBV Technologies compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and DBV Technologies (NASDAQ:DBVT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Amneal Pharmaceuticals has a net margin of 4.01% compared to DBV Technologies' net margin of -2,895.37%. DBV Technologies' return on equity of -129.88% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

Amneal Pharmaceuticals currently has a consensus price target of $15.00, indicating a potential upside of 22.65%. DBV Technologies has a consensus price target of $40.25, indicating a potential upside of 102.87%. Given DBV Technologies' higher probable upside, analysts plainly believe DBV Technologies is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
DBV Technologies	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.67

Amneal Pharmaceuticals has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.05B	1.26	$72.06M	$0.38	32.18
DBV Technologies	N/A	N/A	-$146.95M	-$4.46	N/A

Amneal Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.96, meaning that its stock price is 196% less volatile than the broader market.

In the previous week, Amneal Pharmaceuticals and Amneal Pharmaceuticals both had 4 articles in the media. DBV Technologies' average media sentiment score of 0.47 beat Amneal Pharmaceuticals' score of 0.42 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 1.4% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Amneal Pharmaceuticals beats DBV Technologies on 10 of the 15 factors compared between the two stocks.

How does DBV Technologies compare to MANE?

DBV Technologies (NASDAQ:DBVT) and MANE (NYSE:MANE) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

MANE has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. MANE's return on equity of 0.00% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
MANE	N/A	N/A	N/A

DBV Technologies currently has a consensus price target of $40.25, indicating a potential upside of 102.87%. MANE has a consensus price target of $83.33, indicating a potential downside of 21.27%. Given DBV Technologies' higher possible upside, analysts clearly believe DBV Technologies is more favorable than MANE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.67
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	N/A	N/A	-$146.95M	-$4.46	N/A
MANE	N/A	N/A	N/A	N/A	N/A

In the previous week, DBV Technologies and DBV Technologies both had 4 articles in the media. DBV Technologies' average media sentiment score of 0.47 beat MANE's score of 0.17 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MANE	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

71.7% of DBV Technologies shares are owned by institutional investors. 1.4% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

DBV Technologies beats MANE on 5 of the 9 factors compared between the two stocks.

Get DBV Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DBVT vs. The Competition

Export

Metric	DBV Technologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.10B	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-4.45	18.81	20.87	25.61
Price / Sales	N/A	181.76	521.62	63.45
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	5.32	6.75	9.86	6.71
Net Income	-$146.95M	$24.11M	$3.55B	$333.77M
7 Day Performance	-0.75%	0.11%	-0.26%	0.40%
1 Month Performance	-8.32%	0.87%	1.39%	4.03%
1 Year Performance	72.82%	78.18%	41.07%	36.33%

DBV Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DBVT DBV Technologies	2.929 of 5 stars	$19.84 +1.2%	$40.25 +102.9%	+78.3%	$1.10B	N/A	N/A	80
NNNN Anbio Biotechnology	0.8945 of 5 stars	$29.45 -1.8%	N/A	N/A	$4.37B	$8.65M	N/A	27	Positive News
KNSA Kiniksa Pharmaceuticals International	3.425 of 5 stars	$56.66 -1.7%	$60.86 +7.4%	+130.9%	$4.33B	$677.56M	62.82	220	Positive News
CRNX Crinetics Pharmaceuticals	2.3745 of 5 stars	$40.53 -1.8%	$76.75 +89.4%	+21.1%	$4.27B	$7.70M	N/A	210	Earnings Report Analyst Forecast Analyst Revision
AMRX Amneal Pharmaceuticals	4.1315 of 5 stars	$13.40 +2.2%	$15.00 +12.0%	+65.2%	$4.22B	$3.02B	35.28	8,500	Earnings Report Analyst Upgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DBVT) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DBV Technologies (DBVT) Competitors

DBVT vs. NNNN, KNSA, CRNX, AMRX, and MANE

How does DBV Technologies compare to Anbio Biotechnology?

Summary

How does DBV Technologies compare to Kiniksa Pharmaceuticals International?

Summary

How does DBV Technologies compare to Crinetics Pharmaceuticals?

Summary

How does DBV Technologies compare to Amneal Pharmaceuticals?

Summary

How does DBV Technologies compare to MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT vs. The Competition

DBV Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DBV Technologies (DBVT) Competitors

DBVT vs. NNNN, KNSA, CRNX, AMRX, and MANE

How does DBV Technologies compare to Anbio Biotechnology?

Which has more volatility & risk, DBVT or NNNN?

Which has preferable earnings & valuation, DBVT or NNNN?

Does the media refer more to DBVT or NNNN?

Do analysts recommend DBVT or NNNN?

Is DBVT or NNNN more profitable?

Do institutionals & insiders hold more shares of DBVT or NNNN?

Summary

How does DBV Technologies compare to Kiniksa Pharmaceuticals International?

Do insiders and institutionals believe in KNSA or DBVT?

Does the media prefer KNSA or DBVT?

Which has more risk and volatility, KNSA or DBVT?

Do analysts rate KNSA or DBVT?

Is KNSA or DBVT more profitable?

Which has higher earnings & valuation, KNSA or DBVT?

Summary

How does DBV Technologies compare to Crinetics Pharmaceuticals?

Which has stronger valuation and earnings, CRNX or DBVT?

Does the media favor CRNX or DBVT?

Do institutionals and insiders believe in CRNX or DBVT?

Which has more risk & volatility, CRNX or DBVT?

Is CRNX or DBVT more profitable?

Do analysts rate CRNX or DBVT?

Summary

How does DBV Technologies compare to Amneal Pharmaceuticals?

Is AMRX or DBVT more profitable?

Do analysts rate AMRX or DBVT?

Which has stronger valuation and earnings, AMRX or DBVT?

Which has more risk & volatility, AMRX or DBVT?

Does the media favor AMRX or DBVT?

Do institutionals and insiders believe in AMRX or DBVT?

Summary

How does DBV Technologies compare to MANE?

Is DBVT or MANE more profitable?

Do analysts recommend DBVT or MANE?

Which has higher valuation & earnings, DBVT or MANE?

Does the media favor DBVT or MANE?

Do insiders & institutionals believe in DBVT or MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT vs. The Competition

DBV Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools